Back to results

Efficacy of iOWH032 in Dehydrating Cholera (POC)

Primary Purpose

Secretory Diarrhea

Status

Withdrawn

Phase

Phase 2

Locations

Bangladesh

Study Type

Interventional

Intervention

iOWH032

About this trial

This is an interventional treatment trial for Secretory Diarrhea focused on measuring cholera, diarrhea, secretory diarrhea, ORS, V. cholerae O1, iOWH032, children, pharmacokinetic, Bangladesh

Eligibility Criteria

5 Years - 55 Years (Child, Adult)All SexesDoes not accept healthy volunteers

PART A - ADULTS

***Inclusion Criteria***

A patient will be considered eligible for participation in the study if the following inclusion criteria are satisfied on admission (Day 1) to the Dhaka Hospital of icddr,b:

Adults aged 18 years to 55 years
Duration of illness: History of acute watery diarrhea of less than 24 hours' duration without fever or visible blood in feces
Clinical signs and symptoms of severe dehydration (>10% loss of body weight based on rehydration weight)
Stool RDT and/or stool DF microscopy demonstrating presence of V. cholerae
Must have a purging rate greater than/equal to 20 mL/kg (5 mL/kg/h) during the initial 4- to 6-hour screening/observation period, and signs of clinical dehydration must be corrected
Written informed consent for participation in the study (see Section 6.1.2 for details of the consent process)
Negative urine pregnancy test for all female patients
Nonpregnant and nonlactating females of childbearing potential agree to either abstain from sex or use double barrier contraception (2 contraceptive methods at a time) during the study and until 1 month after the last dose of study drug

***Exclusion Criteria***

A patient with any of the following criteria at screening for study enrollment will not qualify for the study:

Received antidiarrheal medication (eg, loperamide, diphenoxylate) within 7 days before screening
Abnormal ECG findings, with the exception of sinus tachycardia, premature atrial contractions, or ECG intervals within normal limits for sinus rate
Use of drugs metabolized predominantly via CYP2C9 within 7 days before screening (see Section 5.7)
Concomitant infection requiring antimicrobial therapy other than the study drug that may interfere with the evaluation of either the efficacy or safety of the study drug
Patients unwilling or unable to take part in this study or refusing to sign informed consent (patients who participate on the basis of proxy consent will be re-consented at the end of the screening/observation period; those refusing consent at that time will be excluded from further study participation)
Patients previously enrolled in this or any other investigational study within the past 30 days

PART B - PEDIATRIC

***Inclusion Criteria***

A patient will be considered eligible for participation in the study if the following inclusion criteria are satisfied on admission (Day 1) to the Clinical Research Ward (CRW) of Dhaka Hospital:

Pediatric population aged ≥ 5 years to < 18 years of age
Duration of illness: History of acute watery diarrhea of less than 24 hours' duration without fever or visible blood in feces
Clinical signs and symptoms of severe dehydration (>10% loss of body weight based on rehydration weight)
Stool RDT and/or stool DF microscopy demonstrating presence of V. cholerae
Must have a purging rate ≥5 mL/kg/h average during the initial 4- to 6-hour screening/observation period and signs of clinical dehydration must be corrected
Parental consent for all pediatric patients participating in the study and written informed assent for children aged 11-17 years (see Section 6.1.2 for details of the consent process)
Negative urine pregnancy test for female postmenarchal patients
Nonpregnant and nonlactating females of childbearing potential agree to either abstain from sex or use double-barrier contraception (2 contraceptive methods at a time) during the study and until 1 month after the last dose of study drug

***Exclusion Criteria***

A patient with any of the following criteria at screening for study enrollment will not qualify for the study:

Received antidiarrheal medication (eg, loperamide, diphenoxylate) within 7 days before screening
Abnormal ECG findings, with the exception of sinus tachycardia, premature atrial contractions, or ECG intervals within normal limits for sinus rate
Use of drugs metabolized predominantly via CYP2C9 (see Section 5.7) within 7 days before screening
Concomitant infection requiring antimicrobial therapy other than the study drug that may interfere with evaluation of either the efficacy or safety of the study drug
Children or parents/guardians unwilling or unable to take part in this study or refusing to sign informed assent/consent; applicable patients who participate on the basis of proxy assent/consent will be re-assented at the end of the screening/observation period; those refusing assent/consent at that time will be excluded from further study participation
Patients previously enrolled in this or any other investigational study with the past 30 days

Sites / Locations

International Centre for Diarrhoeal Disease Research, Bangladesh

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Arm Label

Part A (Adults)

Part B (Pediatric)

Arm Description

In Part A, approximately 170 adult patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 500 mg or placebo TID for up to 3 days

Following completion of Part A, the data and safety monitoring board (DSMB) will review the unblinded data to assess safety and efficacy and conduct a futility analysis prior to proceeding to Part B. Following the DSMB recommendation of dose and dosing schedule for pediatric patients, Part B will be initiated. Approximately 156 pediatric patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 or placebo at the recommended dose and dosing regimen.

Outcomes

Primary Outcome Measures

Output (mL/kg of body weight) of unformed stools (composite)

The primary objectives of the study are as follows: To evaluate the efficacy of iOWH032 in adults with cholera, as measured by unformed stool output in the first 24 hours after administration (Part A) To determine an effective dose and dosing regimen of iOWH032 in children with cholera (Part A) To evaluate the efficacy of iOWH032 at this recommended dose and dosing regimen in children with cholera (Part B)

Secondary Outcome Measures

Total stool output (mL/kg body weight) (composite)

Total stool output (mL/kg body weight) from randomization until the resolution of diarrhea, or until 3 days (72 hours post-dose) after administration of the first dose of study drug, whichever is sooner Time to resolution of diarrhea Incidence of diarrhea resolution within 48 hours and within 72 hours from the time of administration of the first dose of study drug Intake of ORS solution and plain water in mL/kg from time of randomization through the last unformed stool or until 3 days (72 hours) after administration of the first dose of study drug, whichever is sooner Requirement for unscheduled IV rehydration therapy (mL/kg) after randomization Sodium, potassium, chloride, cAMP, parent drug, and metabolite concentrations, all in the stool Sensitivity, specificity, positive and negative predictive values, and accuracy of stool DF and RDT in the diagnosis of cholera, and the impact of antibiotic therapy on DF and RDT

Full Information

NCT ID

NCT02111304

First Posted

April 1, 2014

Last Updated

September 24, 2014

Sponsor

PATH

Collaborators

Bill and Melinda Gates Foundation

1. Study Identification

Unique Protocol Identification Number

NCT02111304

Brief Title

Efficacy of iOWH032 in Dehydrating Cholera

Acronym

POC

Official Title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Two-Part Trial to Evaluate the Efficacy, Safety, and Tolerability of iOWH032 in the Treatment of Acute Dehydrating Diarrhea in Adult and Pediatric Patients With Cholera

Study Type

Interventional

2. Study Status

Record Verification Date

April 2014

Overall Recruitment Status

Withdrawn

Why Stopped

Trial was never initiated due to PATH executive decision.

Study Start Date

June 2014 (undefined)

Primary Completion Date

January 2016 (Anticipated)

Study Completion Date

May 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

PATH

Collaborators

Bill and Melinda Gates Foundation

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The primary hypothesis is that administration of iOWH032 to adult and pediatric males and females with acute cholera due to V. cholerae O1 reduces stool output in the first 24 hours significantly more than does the current standard of care.

Detailed Description

This is a Phase 2, randomized, double-blind, placebo-controlled study of iOWH032 in adult patients (Part A) and then pediatric patients (Part B) with acute watery diarrhea of less than 24 hours' duration due to cholera. All subjects will be treated with standard of care (IV rehydration fluids, ORS, and azithromycin less than/equal to1 g po) in addition to study drug (iOWH032 active drug or placebo). Patients will be admitted, undergo a 4- to 6-hour screening/observation period, be randomized in the study and treated with study drug (active or placebo) for up to 3 days (ie, up to 9 doses), with a follow-up visit on Day 7. In Part A, approximately 170 adult patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 500 mg or placebo TID for up to 3 days. Following completion of Part A, the data and safety monitoring board (DSMB) will review the unblinded data to assess safety and efficacy and conduct a futility analysis prior to proceeding to Part B. Following the DSMB recommendation of dose and dosing schedule for pediatric patients, Part B will be initiated. Approximately 156 pediatric patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 or placebo at the recommended dose and dosing regimen. The primary efficacy population for Parts A and B will consist of patients who tolerate the first 3 doses of study drug (0, 8, and 16 hours post-randomization) without vomiting and whose diagnosis is subsequently confirmed by a positive culture for V. cholerae O1. The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) Ethics Committee and Western Institutional Review Board (WIRB) will be informed of any serious adverse event (SAE). Occurrence of 2 or more drug-related SAEs within a group of 10 patients (20% of cumulative completed patients in the treatment group) in Part A or Part B will result in unblinding of those patients and review by the DSMB. The study can be halted, discontinued, or amended according to the recommendations of the icddr,b DSMB.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Secretory Diarrhea

Keywords

cholera, diarrhea, secretory diarrhea, ORS, V. cholerae O1, iOWH032, children, pharmacokinetic, Bangladesh

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Parallel Assignment

Masking

ParticipantInvestigator

Allocation

Randomized

Enrollment

0 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Part A (Adults)

Arm Type

Active Comparator

Arm Description

In Part A, approximately 170 adult patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 500 mg or placebo TID for up to 3 days

Arm Title

Part B (Pediatric)

Arm Type

Active Comparator

Arm Description

Intervention Type

Drug

Intervention Name(s)

iOWH032

Primary Outcome Measure Information:

Title

Output (mL/kg of body weight) of unformed stools (composite)

Description

Time Frame

First 24-hour period following randomization

Secondary Outcome Measure Information:

Title

Total stool output (mL/kg body weight) (composite)

Description

Time Frame

From randomization until the resolution of diarrhea, or until 3 days (72 hours post-dose) after administration of the first dose of study drug, whichever is sooner

Other Pre-specified Outcome Measures:

Title

Safety

Description

The safety and tolerability endpoints for this study are AEs, clinical laboratory values, physical examination results, vital signs, and ECG findings. All patients in Part A and B of the study who receive study drug will be included in the safety analysis. Acceptability of the iOWH032 dispersible tablet or suspension formulation will be evaluated in Part B of the study (pediatric patients).

Time Frame

Duration of Study

10. Eligibility

Sex

All

Minimum Age & Unit of Time

5 Years

Maximum Age & Unit of Time

55 Years

Accepts Healthy Volunteers

Eligibility Criteria

Approximately 170 adult (male and female) patients must be enrolled to ensure that 96 patients (48 active and 48 placebo) are evaluable in Part A. In Part B, approximately 156 pediatric patients will be enrolled to ensure that 120 pediatric patients (60 active and 60 placebo) are evaluable for the analysis of 24 hour stool output, the primary outcome measure. PART A - ADULTS ***Inclusion Criteria*** A patient will be considered eligible for participation in the study if the following inclusion criteria are satisfied on admission (Day 1) to the Dhaka Hospital of icddr,b: Adults aged 18 years to 55 years Duration of illness: History of acute watery diarrhea of less than 24 hours' duration without fever or visible blood in feces Clinical signs and symptoms of severe dehydration (>10% loss of body weight based on rehydration weight) Stool RDT and/or stool DF microscopy demonstrating presence of V. cholerae Must have a purging rate greater than/equal to 20 mL/kg (5 mL/kg/h) during the initial 4- to 6-hour screening/observation period, and signs of clinical dehydration must be corrected Written informed consent for participation in the study (see Section 6.1.2 for details of the consent process) Negative urine pregnancy test for all female patients Nonpregnant and nonlactating females of childbearing potential agree to either abstain from sex or use double barrier contraception (2 contraceptive methods at a time) during the study and until 1 month after the last dose of study drug ***Exclusion Criteria*** A patient with any of the following criteria at screening for study enrollment will not qualify for the study: Received antidiarrheal medication (eg, loperamide, diphenoxylate) within 7 days before screening Abnormal ECG findings, with the exception of sinus tachycardia, premature atrial contractions, or ECG intervals within normal limits for sinus rate Use of drugs metabolized predominantly via CYP2C9 within 7 days before screening (see Section 5.7) Concomitant infection requiring antimicrobial therapy other than the study drug that may interfere with the evaluation of either the efficacy or safety of the study drug Patients unwilling or unable to take part in this study or refusing to sign informed consent (patients who participate on the basis of proxy consent will be re-consented at the end of the screening/observation period; those refusing consent at that time will be excluded from further study participation) Patients previously enrolled in this or any other investigational study within the past 30 days PART B - PEDIATRIC ***Inclusion Criteria*** A patient will be considered eligible for participation in the study if the following inclusion criteria are satisfied on admission (Day 1) to the Clinical Research Ward (CRW) of Dhaka Hospital: Pediatric population aged ≥ 5 years to < 18 years of age Duration of illness: History of acute watery diarrhea of less than 24 hours' duration without fever or visible blood in feces Clinical signs and symptoms of severe dehydration (>10% loss of body weight based on rehydration weight) Stool RDT and/or stool DF microscopy demonstrating presence of V. cholerae Must have a purging rate ≥5 mL/kg/h average during the initial 4- to 6-hour screening/observation period and signs of clinical dehydration must be corrected Parental consent for all pediatric patients participating in the study and written informed assent for children aged 11-17 years (see Section 6.1.2 for details of the consent process) Negative urine pregnancy test for female postmenarchal patients Nonpregnant and nonlactating females of childbearing potential agree to either abstain from sex or use double-barrier contraception (2 contraceptive methods at a time) during the study and until 1 month after the last dose of study drug ***Exclusion Criteria*** A patient with any of the following criteria at screening for study enrollment will not qualify for the study: Received antidiarrheal medication (eg, loperamide, diphenoxylate) within 7 days before screening Abnormal ECG findings, with the exception of sinus tachycardia, premature atrial contractions, or ECG intervals within normal limits for sinus rate Use of drugs metabolized predominantly via CYP2C9 (see Section 5.7) within 7 days before screening Concomitant infection requiring antimicrobial therapy other than the study drug that may interfere with evaluation of either the efficacy or safety of the study drug Children or parents/guardians unwilling or unable to take part in this study or refusing to sign informed assent/consent; applicable patients who participate on the basis of proxy assent/consent will be re-assented at the end of the screening/observation period; those refusing assent/consent at that time will be excluded from further study participation Patients previously enrolled in this or any other investigational study with the past 30 days

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Wasif A Khan, MBBS/MHS

Organizational Affiliation

International Centre for Diarrhoeal Disease Research, Bangladesh

Official's Role

Principal Investigator

First Name & Middle Initial & Last Name & Degree

KATM Ehsanul Huq, MBBS/DTM

Organizational Affiliation

International Centre for Diarrhoeal Disease Research, Bangladesh

Official's Role

Principal Investigator

Facility Information:

Facility Name

International Centre for Diarrhoeal Disease Research, Bangladesh

City

Dhaka

ZIP/Postal Code

1212

Country

Bangladesh

12. IPD Sharing Statement

Citations:

Citation

Bardhan PK, Khan WA, Ahmed S, Salam MA, Saha D, Golman D, et al. Evaluation of safety and efficacy of a novel anti-secretory anti-diarrheal agent Crofelemer (NP-303), in combination with a single oral dose of azithromycin for the treatment of acute dehydrating diarrhea caused by Vibrio cholera cholera and other Bacterial Infections: 43rd US-Japan Cooperative Medical Science Program, Kyoto, Japan, November 21, 2008.

Results Reference

background

Citation

Boschi-Pinto C, Lanata CF, Black RE. The global burden of childhood diarrhea. Matern Child Health. 2009;3: 225-243.

Results Reference

background

Citation

Cystic Fibrosis Mutation Database, 2009 [online] Available at: http://www.genet.sickkids.on.ca/cftr/app

Results Reference

background

PubMed Identifier

12480424

Citation

Khan WA, Saha D, Rahman A, Salam MA, Bogaerts J, Bennish ML. Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial. Lancet. 2002 Nov 30;360(9347):1722-7. doi: 10.1016/S0140-6736(02)11680-1.

Results Reference

background

PubMed Identifier

15277574

Citation

Muanprasat C, Sonawane ND, Salinas D, Taddei A, Galietta LJ, Verkman AS. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J Gen Physiol. 2004 Aug;124(2):125-37. doi: 10.1085/jgp.200409059.

Results Reference

background

PubMed Identifier

16641573

Citation

Raghupathy P, Ramakrishna BS, Oommen SP, Ahmed MS, Priyaa G, Dziura J, Young GP, Binder HJ. Amylase-resistant starch as adjunct to oral rehydration therapy in children with diarrhea. J Pediatr Gastroenterol Nutr. 2006 Apr;42(4):362-8. doi: 10.1097/01.mpg.0000214163.83316.41.

Results Reference

background

PubMed Identifier

18368194

Citation

Ram PK, Choi M, Blum LS, Wamae AW, Mintz ED, Bartlett AV. Declines in case management of diarrhoea among children less than five years old. Bull World Health Organ. 2008 Mar;86(3):E-F. doi: 10.2471/blt.07.041384. No abstract available.

Results Reference

background

PubMed Identifier

16760445

Citation

Saha D, Karim MM, Khan WA, Ahmed S, Salam MA, Bennish ML. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med. 2006 Jun 8;354(23):2452-62. doi: 10.1056/NEJMoa054493.

Results Reference

background

Citation

StataCorp. POWERCAL: Stata module to perform general power and sample size calculations. http://ideas.repec.org/c/boc/bocode/s422401.html. 2013. Stata Statistical Software: Release 13. StataCorp LP, College Station, TX.

Results Reference

background

Citation

United Nations Children's Fund (UNICEF) and World Health Organization (WHO). Diarrhoea: Why children are still dying and what can be done. 2009. New York and Geneva.

Results Reference

background

PubMed Identifier

19153558

Citation

Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov. 2009 Feb;8(2):153-71. doi: 10.1038/nrd2780. Epub 2008 Jan 19.

Results Reference

background

PubMed Identifier

11100619

Citation

Victora CG, Bryce J, Fontaine O, Monasch R. Reducing deaths from diarrhoea through oral rehydration therapy. Bull World Health Organ. 2000;78(10):1246-55.

Results Reference

background

Citation

World Health Organization. The rational use of drugs in the management of acute diarrhoea in children. WHO, Geneva, 1990.

Results Reference

background

PubMed Identifier

16966475

Citation

Zhou Z, Wang X, Liu HY, Zou X, Li M, Hwang TC. The two ATP binding sites of cystic fibrosis transmembrane conductance regulator (CFTR) play distinct roles in gating kinetics and energetics. J Gen Physiol. 2006 Oct;128(4):413-22. doi: 10.1085/jgp.200609622. Epub 2006 Sep 11.

Results Reference

background

Learn more about this trial

Efficacy of iOWH032 in Dehydrating Cholera

We'll reach out to this number within 24 hrs